8-K: Replimune Advances Oncolytic Immunotherapy Programs

Replimune Group, Inc. provides an updated corporate presentation highlighting recent business and strategic developments, positive clinical data for RP1 and RP2, and readiness for commercial launch.

Summary

• A PDUFA date of April 10, 2026, is set for RP1 in melanoma.
• The commercial team is launch-ready with an optimized go-to-market model and approximately 150 accounts prepared for day one.
• The RPx platform has successfully completed approximately 1,200 deep injections, including in liver and lung lesions, demonstrating safety and feasibility.
• Approximately 1,000 patients have been treated across the RPx platform.
• The IGNYTE study in anti-PD-1 failed melanoma showed an Objective Response Rate (ORR) of 21.4% (N=140) with a Complete Response (CR) rate of 17.1%.
• Enrollment for the confirmatory IGNYTE-3 study is on track, with an interim Overall Survival (OS) analysis planned for the second half of 2027.
• RP1 monotherapy demonstrated a 34.6% ORR in locally advanced Cutaneous Squamous Cell Carcinoma (CSCC) in Solid Organ Transplant (SOT) patients (ARTACUS study), with durable responses.
• RP1 monotherapy in low-risk, resectable neoadjuvant cSCC achieved a 100% clinical ORR and 83% pathological ORR, with 33% clinical CR.
• RP2 plus nivolumab in metastatic uveal melanoma showed a 29.4% ORR (N=17) with a median Duration of Response (DOR) of 11.5 months.
• The registrational Phase 2/3 REVEAL study for metastatic uveal melanoma is ongoing with approximately 50 patients enrolled, and a Phase 2/3 transition expected in Q1 2027.
• The RP2 HCC/BTC (Hepatocellular Carcinoma/Biliary Tract Cancer) Phase 1 cohort is enrolling, with preliminary HCC data anticipated in the second half of 2026.
• The company reported cash of $269.2 million as of December 31, 2025 (unaudited).
• An in-house U.S.-based manufacturing facility is ready for commercial supply of RP1.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data across multiple programs, a clear path to commercialization with a near-term PDUFA date, and a solid cash position, indicating significant progress and future potential.

Positives

• A near-term PDUFA date of April 10, 2026, for RP1 in melanoma provides a clear regulatory pathway to market.
• Strong clinical data for RP1 in anti-PD-1 failed melanoma, demonstrating a 21.4% ORR and 17.1% CR in a highly resistant patient population.
• Durable responses observed with RP1 monotherapy in difficult-to-treat settings such as locally advanced CSCC in SOT patients and low-risk, resectable neoadjuvant cSCC.
• Commercial launch readiness is well advanced, with an optimized go-to-market model and approximately 150 accounts prepared for initial rollout.
• Successful and safe execution of approximately 1,200 deep/visceral injections (including liver and lung) expands the potential treatment applications of the RPx platform.
• The company's in-house U.S. manufacturing facility is fully prepared for commercial supply, ensuring product availability.
• Significant addressable patient populations across various cancers, including approximately 10,000 in U.S. melanoma and up to approximately 130,000 across the broader RPx pipeline, indicate substantial market opportunity.

Risks

• Limited operating history of the company.
• Uncertainty regarding the ability to generate consistently positive clinical trial results for product candidates.
• Potential for unforeseen costs and timing challenges in operating the in-house manufacturing facility.
• Risks associated with the timing and scope of regulatory approvals.
• Exposure to changes in laws and regulations.
• Competitive pressures from other therapeutic approaches and companies.
• Challenges in identifying additional product candidates for development.
• Impact of political and global macro factors, including global pandemics, ongoing military conflicts (Russia-Ukraine, Israel-Hamas), and related governmental sanctions, on operations and the global economy.

Future Outlook

The company is strategically positioned for the commercial launch of RP1 in melanoma following its PDUFA date in April 2026. It plans to significantly expand the RPx platform into additional skin cancers and deep/visceral indications such as HCC and BTC, supported by multiple ongoing clinical trials and anticipated data readouts throughout 2026 and 2027.

Management Comments

• "Igniting a systemic immune response to cancer with oncolytic immunotherapy."
• "Poised to Deliver on the Promise of Oncolytic Immunotherapy."
• "If we can biopsy the tumor, we can inject it."
• "There is a rising interest in intra-tumoral therapies with IRs."
• "Seeing this level of RP1 activity in visceral un-injected lesions is very motivating for IRs. This is not something we have seen with other intra-tumoral agents to date."
• "Its incredibly exciting, all but 2 lesions were composite CRs! Nobody had any AEs of any kind other than some local erythema or itching. A well tolerated, effective alternative to surgery for small SCCs!!!"

Industry Context

Oncolytic immunotherapy, particularly Replimune's RPx platform, is positioned to address significant unmet needs in cancer treatment by activating a systemic immune response, especially in cases resistant to conventional therapies. The demonstrated capability for deep/visceral injections expands the applicability of these therapies to a broader spectrum of cancers and metastatic sites. The growing interest from interventional radiologists in intra-tumoral therapies suggests a potential evolution in cancer treatment paradigms, integrating image-guided procedures for enhanced therapeutic delivery.

Comparison to Industry Standards

• The RPx platform is presented as "overcoming historical hurdles" in oncolytic immunotherapy, suggesting an advancement beyond previous limitations in the field.
• The IGNYTE study demonstrated a "clinically meaningful ORR in resistant subgroups" of anti-PD-1 failed melanoma, indicating a reversal of resistance mechanisms compared to prior treatments.
• Responses with RP1 plus Nivolumab in the IGNYTE Study showed a superior ORR (29.8% vs. 11.5%) and a significantly longer median time to progression for responders (30.62 months vs. 4.40 months) compared to the immediate prior anti-PD-1 regimen.
• RP1 monotherapy in Solid Organ Transplant (SOT) CSCC addresses a "significant unmet need" where optimal management is not well established, positioning it as a potential new standard.
• The observed level of RP1 activity in visceral un-injected lesions is noted as "not something we have seen with other intra-tumoral agents to date," highlighting a potentially differentiated efficacy profile.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, a near-term regulatory milestone, and commercialization readiness, potentially leading to increased valuation.
• Patients: Potential for new, effective treatment options for difficult-to-treat cancers, especially those resistant to prior immunotherapies or with deep/visceral metastases.
• Healthcare Providers (Oncologists, Interventional Radiologists): New therapeutic tools and treatment paradigms, particularly with the involvement of interventional radiologists for deep injections.
• Employees: Positive outlook due to company growth, commercial launch, and ongoing research and development.

Next Steps

• PDUFA date for RP1 in melanoma on April 10, 2026.
• Commercial launch of RP1 in melanoma.
• Enrollment completion and interim OS analysis for IGNYTE-3 study in 2H 2027.
• Phase 2/3 transition for REVEAL study in Q1 2027.
• Preliminary HCC data expected in 2H 2026.
• Continued expansion of RPx platform into other skin cancers and deep/visceral indications.

Key Dates

Recommendation

The filing details compelling positive clinical data for RP1 and RP2 across multiple challenging cancer indications, including anti-PD-1 failed melanoma, SOT CSCC, and metastatic uveal melanoma. A critical PDUFA date for RP1 in melanoma is imminent (April 10, 2026), positioning the company for its first commercial launch with a well-prepared go-to-market strategy and manufacturing capabilities. The successful deep injection capabilities significantly expand the addressable market. These factors, combined with a healthy cash balance and multiple ongoing trials with future data readouts, suggest strong near-term catalysts and long-term growth potential, making it an attractive investment.

Keywords

Oncolytic immunotherapy, Melanoma, RP1, RP2, Nivolumab, Uveal melanoma, Cutaneous squamous cell carcinoma, HCC, BTC, Cancer treatment, Clinical trials, PDUFA, FDA, Oncology, Biotechnology